Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: AEON Biopharma Inc., 3 years.
AEON Biopharma Inc.
Director
LENZ Therapeutics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
LENZ Therapeutics Inc. June 12, 202698.9%
-
AEON Biopharma Inc. June 14, 20240.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 17, 2026 | AEON Biopharma Inc. | Grant or award | +222,684 | — | — |
| Apr 14, 2025 | RxSight Inc. | Option exercise | +7,792 | $4.34 | $33,817 |
| Oct 1, 2024 | RxSight Inc. | Option exercise | +15,000 | $16.00 | $240,000 |
| Oct 1, 2024 | RxSight Inc. | Open-market sale | −5,201 | $47.96 | $249,440 |
| Oct 1, 2024 | RxSight Inc. | Open-market sale | −9,521 | $48.69 | $463,577 |
| Oct 1, 2024 | RxSight Inc. | Open-market sale | −278 | $49.45 | $13,747 |
| Aug 31, 2024 | AEON Biopharma Inc. | Grant or award | +36,021 | — | — |
| Jul 15, 2024 | RxSight Inc. | Option exercise | +16,505 | $4.34 | $71,632 |
| Jul 1, 2024 | RxSight Inc. | Option exercise | +10,000 | $15.60 | $156,000 |
| Jul 1, 2024 | RxSight Inc. | Open-market sale | −8,146 | $58.41 | $475,808 |
| Jul 1, 2024 | RxSight Inc. | Open-market sale | −1,854 | $59.48 | $110,276 |
| Jul 1, 2024 | RxSight Inc. | Open-market sale | −6,599 | $58.55 | $386,371 |
| Jul 1, 2024 | RxSight Inc. | Open-market sale | −1,803 | $59.56 | $107,387 |
| May 1, 2024 | RxSight Inc. | Option exercise | +10,247 | $15.60 | $159,853 |
| May 1, 2024 | RxSight Inc. | Open-market sale | −9,620 | $52.68 | $506,782 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.